Novartis to acquire Avidity Biosciences for $12 billion
26/10/2025 17:05
Oct 26 (Reuters) - Swiss drugmaker Novartis NOVN.S on Sunday said it agreed to acquire Avidity Biosciences for $12 billion. (Reporting by Angela Christy in Bengaluru) ((AngelaChristy.M@thomsonreuters.com;))
Recent news on Avidity Biosciences
See all newsFactbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
Factbox: Pharma sector doubles down on AI amid hopes of slashing costs, timelines
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM
Brief: Avidity Biosciences Says Record Date Set For February 12, 2026 For Spin-Off